June 17, 2022
1 min watch
Chen Y, et al. Pharmacogenomics — One step closer to precision medicine in headache? A pilot, exploratory study of the effect of pharmacogenomic phenotypes on the adequate dosing of Verapamil for migraine prevention. Presented at: American Headache Society annual scientific meeting; June 9-12, 2022; Denver.
Chen reports no relevant financial disclosures.
DENVER — Verapamil was shown to be tolerable for migraine prevention at a maximum dose of 20 mg to 480 mg per day, Yi-Chieh Chen, PharmD, said at the American Headache Society’s annual scientific meeting.
“We found a wide range of minimally effective and tolerable verapamil doses in a cohort with various pharmacogenomic phenotypes,” Chen, of the Mayo Clinic in Rochester, Minnesota, said.